Effectiveness of probiotics in irritable bowel syndrome:Updated systematic review with meta-analysis

作     者：Tina Didari Shilan Mozaffari Shekoufeh Nikfar Mohammad Abdollahi 

作者机构：Department of Toxicology and Pharmacology Faculty of Pharmacy and Pharmaceutical Sciences Research CenterTehran University of Medical Sciences Department of Pharmacoeconomics and Pharmaceutical Administration Faculty of Pharmacy and Pharmaceutical Policy Research CenterTehran University of Medical Sciences 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2015年第21卷第10期

页      面：3072-3084页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Evidence-based medicine Irritable bowel syndrome M 

摘      要：AIM:To investigate the efficacy of probiotics in irritable bowel syndrome(IBS) ***:Pub Med,Cochrane library,Scopus,Google Scholar,and *** databases were searched for literature published between September 2007 and December *** applied Mesh terms were probiotics, irritable bowel syndrome, and irritable bowel syndrome treatment. The collected data contained24 clinical trials,of which 15 were eligible for meta-analysis and nine were reviewed *** studies were randomized placebo-controlled trials in patients with IBS that investigated the efficacy of probiotics in IBS *** Jadad score was used to assess the methodological quality of *** quality scale ranges from 0 to 5 points,with a score ≤ 2 indicating a low quality report,and a score of ≥3 indicating a high quality *** risk(RR),standardized effect size,and 95%CI were calculated using the Der Simonian-Laird *** Cochran Q test was used to test heterogeneity with P *** plots were constructed and Egger s and BeggMazumdar tests were performed to assess publication ***:A total of 1793 patients were included in the *** RR of responders to therapies based on abdominal pain score in IBS patients for two included trials comparing probiotics to placebo was 1.96(95%CI:1.14-3.36;P = 0.01).RR of responders to therapies based on a global symptom score in IBS patients for two included trials comparing probiotics with placebo was 2.43(95%CI:1.13-5.21;P = 0.02).For adequate improvement of general symptoms in IBS patients,the RR of seven included trials(six studies) comparing probiotics with placebo was 2.14(95%CI:1.08-4.26;P = 0.03).Distension,bloating,and flatulence were evaluated using an IBS severity scoring system in three trials(two studies) to compare the effect of probiotic therapy in IBS patients with placebo,the standardized effect size of mean differences for probiotics therapy was-2.57(95%CI:-13.05--7.92)